Patients who Have Dilated Cardiomyopathy Must Have a Trial of Bridge to Recovery (Pro)

Heart Failure Clinics

Volumn 3, Issue 3, 2007, Pages 299-315

  Mueller, Johannes ^a   Wallukat, Gerd ^b  

^a Berlin Heart AG   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROCOLLAGEN;

BLEEDING; BLOOD; CARDIOVASCULAR EQUIPMENT; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONVALESCENCE; DEVICE REMOVAL; DOCUMENTATION; EXPERIENCE; FOLLOW UP; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART TRANSPLANTATION; HUMAN; IMPLANTATION; LIFESPAN; PREDICTION; RECURRENT DISEASE; REVIEW; RISK; SURGICAL TECHNIQUE; THROMBOEMBOLISM; WEANING;

BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; CARDIOMYOPATHY, DILATED; HEART FUNCTION TESTS; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; PATIENT SELECTION; PROSTHESIS DESIGN; PROSTHESIS FAILURE; RECURRENCE; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34548172736     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2007.05.006     Document Type: Review

References (132)

1. Müller J., Wallukat G., Weng Y.G., et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation 96 2 (1997) 542-549
2. Rose E.A., and Frazier O.H. Resurrection after mechanical circulatory support. Circulation 96 2 (1997) 393-395
3. Oz M.C., Argenziano M., Catanese K.A., et al. Are they an alternative to transplantation?. Circulation 95 7 (1997) 1844-1852
4. Mancini D.M., Beniaminovitz A., Levin H., et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation 98 22 (1998) 2383-2389
5. McCarthy P.M., Smedira N.O., Vargo R.L., et al. One hundred patients with the HeartMate left ventricular assist device: evolving concepts and technology. J Thorac Cardiovasc Surg 115 4 (1998) 904-912
6. Loebe M., Muller J., and Hetzer R. Ventricular assistance for recovery of cardiac failure. Curr Opin Cardiol 14 3 (1999) 234-248
7. Hetzer R., Muller J., Weng Y., et al. Cardiac recovery in dilated cardiomyopathy by unloading with a left ventricular assist device. Ann Thorac Surg 68 2 (1999) 742-749
8. Levin H.R., Oz M.C., Catanese K.A., et al. Transient normalization of systolic and diastolic function after support with a left ventricular assist device in a patient with dilated cardiomyopathy. J Heart Lung Transplant 15 8 (1996) 840-842
9. Levin H.R., Oz M.C., Chen J.M., et al. Reversal of chronic ventricular dilation in patients with end_stage cardiomyopathy by prolonged mechanical unloading. Circulation 91 11 (1995) 2717-2720
10. Prockop D.J., Kivirikko K.I., Tuderman L., et al. The biosynthesis of collagen and its disorders (first of two parts). N Engl J Med 301 1 (1979) 13-23
11. Prockop D.J., Kivirikko K.I., Tuderman L., et al. The biosynthesis of collagen and its disorders (second of two parts). N Engl J Med 301 2 (1979) 77-85
12. Marijianowski M.M., Teeling P., Mann J., et al. Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment. J Am Coll Cardiol 25 6 (1995) 1263-1272
13. Hall S.A., Cigarroa C.G., Marcoux L., et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 25 5 (1995) 1154-1161
14. Greenberg B., Quinones M.A., Koilpillai C., et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 91 10 (1995) 2573-2581
15. Dasse K.A., Frazier O.H., Lesniak J.M., et al. Clinical responses to ventricular assistance versus transplantation in a series of bridge to transplant patients. ASAIO J 38 3 (1992) M622-M626
16. DeRose Jr. J.J., Umana J.P., Argenziano M., et al. Implantable left ventricular assist devices provide an excellent outpatient bridge to transplantation and recovery. J Am Coll Cardiol 30 7 (1997) 1773-1777
17. Hertz M.I., Taylor D.O., Trulock E.P., et al. The registry of the international society for heart and lung transplantation: nineteenth official report-2002. J Heart Lung Transplant 21 9 (2002) 950-970
18. Hung T.C., Butter D.B., Yie C.L., et al. Effects of long_term Novacor artificial heart support on blood rheology. ASAIO Trans 37 3 (1991) M312-M313
19. McGee M.G., Myers T.J., Abou-Awdi N., et al. Extended support with a left ventricular assist device as a bridge to heart transplantation. ASAIO Trans 37 3 (1991) M425-M426
20. Noon G.P., Morley D., Irwin S., et al. Development and clinical application of the MicroMed DeBakey VAD. Curr Opin Cardiol 15 3 (2000) 166-171
21. Siegenthaler M.P., Martin J., van de Loo A., et al. Implantation of the permanent Jarvik-2000 left ventricular assist device: a single-center experience. J Am Coll Cardiol 39 11 (2002) 1764-1772
22. Christiansen S., Van Aken H., Breithardt G.G., et al. Successful cardiac transplantation after 4 cases of DeBakey left ventricular assist device failure. J Heart Lung Transplant 21 6 (2002) 706-709
23. Westaby S., Frazier O.H., Beyersdorf F., et al. The Jarvik 2000 Heart. Clinical validation of the intraventricular position. Eur J Cardiothorac Surg 22 2 (2002) 228-232
24. Pankuweit S., Hufnagel G., Eckhardt H., et al. Cardiotropic DNA viruses and bacteria in the pathogenesis of dilated cardiomyopathy with or without inflammation. Med Klin 93 4 (1998) 223-228
25. Mahon N.G., Zal B., Arno G., et al. Absence of viral nucleic acids in early and late dilated cardiomyopathy. Heart 86 6 (2001) 687-692
26. Klein R.M., Vester E.G., Brehm M.U., et al. Inflammation of the myocardium as an arrhythmia trigger. Z Kardiol 89 Suppl 3 (2000) 24-35
27. Mueller J., and Hetzer R. Left ventricular recovery during left ventricular assist device support. In: Goldstein D.J., and Oz M.C. (Eds). Cardiac assist devices (2000), Futura Publishing Company, Armonk (NY) 121-136
28. Hendry P.J., Masters R.G., Mussivand T.V., et al. Circulatory support for cardiogenic shock due to acute myocardial infarction: a Canadian experience. Can J Cardiol 15 10 (1999) 1090-1094
29. Sukehiro S., and Flameng W. Effects of left ventricular assist for cardiogenic shock on cardiac function and organ blood flow distribution. Ann Thorac Surg 50 3 (1990) 374-383
30. Miyama M. Renal, intestinal and whole body metabolic changes in pig LVAD model. Hokkaido Igaku Zasshi 74 4 (1999) 331-337
31. Tevaearai H.T., Mueller X.M., Jegger D., et al. Atrial, ventricular, or both cannulation sites to optimize left ventricular assistance?. ASAIO J 47 3 (2001) 261-265
32. Yacoub M.H., Tansley P., Birks E.J., et al. A novel combination therapy to revers end-stage heart failure. Transplantation Proceedings 33 (2001) 2762-2764
33. Maybaum S., Williams M., Barbone A., et al. Assessment of synchrony relationships between the native left ventricle and the HeartMate left ventricular assist device. J Heart Lung Transplant 21 5 (2002) 509-515
34. Hetzer R., Weng Y., Potapov E.V., et al. First experiences with a novel magnetically suspended axial flow left ventricular assist device. Eur J Cardiothorac Surg 25 6 (2004) 964-970
35. Yacoub M.H. A novel strategy to maximize the efficacy of left ventricular assist devices as bridge to recovery. Eur Heart J 22 (2002) 534-540
36. Wong K., Boheler K.R., Petrou M., et al. Pharmacological modulation of pressure-overload cardiac hypertrophy: changes in ventricular function, extracellular matrix, and gene expression. Circulation 96 7 (1997) 2239-2246
37. Wong K., Boheler K.R., Bishop J., et al. Clenbuterol induces cardiac hypertrophy with normal functional, morphological and molecular features. Cardiovasc Res 37 1 (1998) 115-122
38. Weber KT. Targeting pathological remodelling: concepts of cardioprotection and reparation. Circulation 200(102):1342-45.
39. Hunt S.A., Baker D.W., Chin M.H., et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure).; International Society for Heart and Lung Transplantation.; Heart Failure Society of America. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 104 24 (2001) 2996-3007
40. Ahmed A. American College of Cardiology/American Heart Association. Chronic heart failure evaluation and management guidelines: relevance to the geriatric practice. J Am Geriatr Soc 51 1 (2003) 123-126
41. Beuckelmann D.J. [Hormonal hyperactivity in heart failure. Differences in beta blockers]. Herz 27 Suppl 1 (2002) 9-15 [in German]
42. Stanek B., Frey B., Hulsmann M., et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38 2 (2001) 436-442
43. Aronson D., and Burger A.J. Effect of beta-blockade on autonomic modulation of heart rate and neurohormonal profile in decompensated heart failure. Ann Noninvasive Electrocardiol 6 2 (2001) 98-106
44. Willenbrock R., Philipp S., Mitrovic V., et al. Neurohumoral blockade in CHF management. J Renin Angiotensin Aldosterone Syst 1 Suppl 1 (2000) 24-30
45. Brilla C.G., Rupp H., Funck R., et al. The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Eur Heart J 16 Suppl O (1995) 107-109
46. Barnes P.J. Therapy of chronic obstructive pulmonary disease. Pharmacol Ther 97 1 (2003) 87-94
47. Landmesser U., Spiekermann S., Dikalov S., et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106 24 (2002) 3073-3078
48. Kumar D., Lou H., and Singal P.K. Oxidative stress and apoptosis in heart dysfunction. Herz 27 7 (2002) 662-668
49. Sun Y., Zhang J., Lu L., et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161 5 (2002) 1773-1781
50. Nakamura R., Egashira K., Machida Y., et al. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. Circulation 106 3 (2002) 362-367
51. Farquharson C.A., Butler R., Hill A., et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106 2 (2002) 221-226
52. Doehner W., Schoene N., Rauchhaus M., et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo_controlled studies. Circulation 105 22 (2002) 2619-2624
53. Nakamura K., Kusano K., Nakamura Y., et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 105 24 (2002) 2867-2871
54. Zafari A.M., and Harrison D.G. Free radicals in heart failure: therapeutic targets for old and new drugs. Congest Heart Fail 8 3 (2002) 129-130
55. Sawyer D.B., Siwik D.A., Xiao L., et al. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 34 4 (2002) 379-388
56. Yap C.L., Anderson K.E., Hughan S.C., et al. Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin alpha(IIb)beta(3). Blood 99 1 (2002) 151-158
57. Vogel J., Bendas G., Bakowsky U., et al. The role of glycolipids in mediating cell adhesion: a flow chamber study. Biochim Biophys Acta 1372 2 (1998) 205-215
58. Ho M., Maple C., Bancroft A., et al. The beneficial effects of omega_3 and omega_6 essential fatty acid supplementation on red blood cell rheology. Prostaglandins Leukot Essent Fatty Acids 61 1 (1999) 13-17
59. Westerveld H.T., de Graaf J.C., van Breugel H.H., et al. Effects of low-dose EPA-E on glycemic control, lipid profile, lipoprotein(a), platelet aggregation, viscosity, and platelet and vessel wall interaction in NIDDM. Diabetes Care 16 5 (1993) 683-688
60. Ernst E. Effects of n-3 fatty acids on blood rheology. J Intern Med Suppl 225 731 (1989) 129-132
61. Cartwright I.J., Pockley A.G., Galloway J.H., et al. The effects of dietary omega-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability and blood viscosity in healthy volunteers. Atherosclerosis 55 3 (1985) 267-281
62. Di Carlo A., Passi S., Ippolito F., et al. Free radical scavenger activity of rutosides. Minerva Cardioangiol 50 6 (2002) 701-707
63. Tretjakovs P., Kalnins U., Dabina I., et al. Nitric oxide production and arachidonic acid metabolism in platelet membranes of coronary heart disease patients with and without diabetes. Med Princ Pract 12 1 (2003) 10-16
64. Kudo I., and Murakami M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat (2002) 68-69 3-58
65. Weyrich A.S., Prescott S.M., and Zimmerman G.A. Platelets, endothelial cells, inflammatory chemokines, and restenosis: complex signaling in the vascular play book. Circulation 106 12 (2002) 1433-1435
66. Feigenbaum H. Echocardiographic evaluation of cardiac chambers. In: Feigenbaum H. (Ed). Echocardiography (1994), Lea & Febiger, Philadelphia 134-180
67. Lejemtel T.H., Sonnenblick E.H., and Frishmann W. Diagnosis and management of heart failure. In: Alexander R.W., Schlant R.C., and Fuster V. (Eds). Hursts the heart. 9th edition (1998), McGraw-Hill, New York 745-781
68. Feigenbaum H. Echocardiographic examination of the left ventricle. Circulation 51 (1975) 1-7
69. Feigenbaum H. Echocardiography. In: Braunwald E. (Ed). Heart disease. 4th edition (1992), W.B. Saunders Co., Philadelphia 64-115
70. Vuille C., and Weyman A.E. Left ventricle I. General considerations, assessment of chamber size and function. In: Weyman A.E. (Ed). Principles an practice of echocardiography. 2nd edition (1994), Lea & Febiger, Philadelphia 557-624
71. De Simone G., Devereux R.B., Roman M.J., et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 23 (1994) 1444-1451
72. Reichek N., Wilson J., St. John Sutton M., et al. Noninvasive determination of left ventricular end systolic stress: validation of the method and initial application. Circulation 65 (1982) 99-108
73. Aurigemma G.P., Douglass P.S., and Gaasch W.H. Quantitative evaluation of left ventricular structure, wall stress and systolic function. In: Otto C.M. (Ed). The practice of clinical echocardiography (1997), W.B. Saunders Co., Philadelphia 1-24
74. Hurrell D.G., Nishimura R.A., Istrup D.M., et al. Utility of preload alteration in assessment of ventricular filling pressure by Doppler echocardiography: a simultaneous characterization and Doppler echocardiographic study. J Am Coll Cardiol 30 (1997) 459-467
75. Lewis J.F. Doppler and two-dimensional echocardiographic evaluation in acute and long-term management of the heart failure patient. In: Otto C.M. (Ed). The practice of clinical echocardiography (1997), W.B. Saunders Co., Philadelphia 433-448
76. Birks E.J., Tansley P.D., Hardy J., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 355 (2006) 1873-1884
77. Dandel M., Weng Y., Siniawski H., et al. Long-term results in patients after weaning from left ventricular assist device. Circulation 112 Suppl I (2005) I-37-I-45
78. Nadruz Jr. W., Kobarg C.B., Constancio S.S., et al. Load-induced transcriptional activation of c-jun in rat myocardium: regulation by myocyte enhancer factor 2. Circ Res 92 2 (2003) 243-251
79. Takeda N. Cardiomyopathy: molecular and immunological aspects. [review]. Int J Mol Med 11 1 (2003) 13-16
80. Gauntt C., and Huber S. Coxsackievirus experimental heart diseases. Front Biosci 8 (2003) E23-E35
81. Caforio A.L., Mahon N.J., Tona F., et al. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail 4 4 (2002) 411-417
82. Kühl U., and Schultheiss H.-P. What is dilated cardiomyopathy?. In: Hetzer R., Hennig E., and Loebe M. (Eds). Mechanical circulatory support (1997), Steinkopff Verlag, Darmstadt (Germany) 69-82
83. Katz A.M. Cardiomyopathy of overload, a major development of prognosis in congestive heartfailure. N Engl J Med 222 (1990) 100-110
84. Lorrell B.H., and Carabello B.A. Left ventricular hypertrophy pathogenesis, detection and prognosis. Circulation 102 (2000) 470-479
85. Swynghedauw B. Molecular mechanisms of myocardial remodelling. Physiol Rev 79 (1999) 216-261
86. Francis G.S. Changing the remodelling process in heart failure. Basic mechanisms and laboratory results. Curr Opin Cardiol 13 (1998) 156-161
87. Hunter J.J., and Chien K.R. Signalling pathways for cardiac hypertrophy and failure. N Engl J Med 341 (1999) 1276-1283
88. Sugden P.H. Signaling in myocardial hypertrophy. Circ Res 84 (1999) 633-646
89. Onodera T., Tamura T., Said S., et al. Maladaptive remodelling of cardiac myocyte shape begins long before failure in hypertension. Hypertension 32 (1998) 753-757
90. Gerdes A.M., Tamura T., Wang X., et al. Myocyte remodelling during the progression to failure in rats with hypertension. Hypertension 28 (1996) 604-614
91. Gerdes A.M., Kellermann S.E., Moore J.A., et al. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation 86 2 (1992) 426-430
92. Gerdes A.M., and Capasso J.M. Structural remodelling and mechanical dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol 27 (1995) 849-856
93. Chien K.R. Stress pathways and heart failure. Cell 98 (1999) 555-558
94. Schneider M.D., and Schwartz R.J. Chips ahoy: gene expression in hearts surveyed by high-density microarrays. Circulation 102 (2000) 3020-3027
95. Corbett J.M., Why H.J., Wheeler C.H., et al. Cardiac protein abnormalities in cardiomyopathy detected by twodimensional polyacrylamide gel electrophoresis. Electrophoresis 19 (1998) 2031-2042
96. Latif N., Khan M., Birks E., et al. Upregulation of the Bcl-2 family of proteins in end-stage heart failure. J Am Coll Cardiol 35 (2000) 1769-1777
97. Chen X., Piacentino III V., Furukawa S., et al. L-type Ca2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices. Circ Res 91 6 (2002) 517-524
98. de Jonge N., van Wichen D.F., Schipper M.E., et al. Left ventricular assist device in end-stage heart failure: persistence of structural myocyte damage after unloading. An immunohistochemical analysis of the contractile myofilaments. J Am Coll Cardiol 39 6 (2002) 963-969
99. Milting H., EL-Banayosy A., Kassner A., et al. The time course of natriuretic hormones as plasma markers of myocardial recovery in heart transplant candidates during ventricular assist device support reveals differences among device types. J Heart Lung Transplant 20 9 (2001) 949-955
100. Li Y.Y., Feng Y., McTiernan C.F., et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 104 10 (2001) 1147-1152
101. Ogletree-Hughes M.L., Stull L.B., Sweet W.E., et al. Mechanical unloading restores beta-adrenergic responsiveness and reverses receptor downregulation in the failing human heart. Circulation 104 8 (2001) 881-886
102. Bruckner B.A., Stetson S.J., Perez-Verdia A., et al. Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. J Heart Lung Transplant 20 4 (2001) 457-464
103. Arbustini E., Grasso M., Porcu E., et al. Healing of acute myocarditis with left ventricular assist device: morphological recovery and evolution to the aspecific features of dilated cardiomyopathy. Ital Heart J 2 1 (2001) 55-59
104. Bruckner B.A., Stetson S.J., Farmer J.A., et al. The implications for cardiac recovery of left ventricular assist device support on myocardial collagen content. Am J Surg 180 6 (2000) 498-501 [discussion: 501-2]
105. Mital S., Loke K.E., Addonizio L.J., et al. Left ventricular assist device implantation augments nitric oxide dependent control of mitochondrial respiration in failing human hearts. J Am Coll Cardiol 36 6 (2000) 1897-1902
106. Torre-Amione G., Stetson S.J., Youker K.A., et al. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: a potential mechanism for cardiac recovery. Circulation 100 11 (1999) 1189-1193
107. Loebe M., Gorman K., Burger R., et al. Complement activation in patients undergoing mechanical circulatory support. ASAIO J 44 5 (1998) M340-M346
108. Dipla K., Mattiello J.A., Jeevanandam V., et al. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 97 23 (1998) 2316-2322
109. McCarthy P.M., Nakatani S., Vargo R., et al. Structural and left ventricular histologic changes after implantable LVAD insertion. Ann Thorac Surg 59 3 (1995) 609-613
110. Birks E.J., Latif N., and Bowles C. Measurement of cytokine levels and activation of the apoptotic pathway in patients requiring left ventricular assist device (LVAD): implication for timing of implantation. Circulation 99 (1999) 2565-2570
111. Dec G.W., and Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 331 (1994) 1564-1575
112. Kopecky S.L., and Gersh B.J. Dilated cardiomyopathy and myocarditis: natural history, etiology, clinical manifestations, and management. Curr Probl Cardiol 12 (1987) 573-647
113. Pauschinger M., Chandrasekharan K., Li J., et al. Mechanisms of extracellular matrix remodeling in dilated cardiomyopathy. Herz 27 (2002) 677-682
114. Maisch B. Ventricular remodeling. Cardiology 87 Suppl 1 (1996) 2-10
115. Maisch B. Extracellular matrix and cardiac interstitium: restriction is not a restricted phenomenon. Herz 20 (1995) 75-80
116. Frank J.S., and Langer G.A. The myocardial interstitium: its structure and its role in ionic exchange. J Cell Biol 60 (1974) 586-601
117. Weber K.T., Janicki J.S., Shroff S.G., et al. Collagen remodeling of the pressure-overload, hypertrophied non-human primate myocardium. Circ Res 62 (1988) 757-765
118. Li J., Schwimmbeck P.L., Tschope C., et al. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res 56 (2002) 235-247
119. Spinale F.G., Coker M.L., Heung L.J., et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102 (2000) 1944-1949
120. Gunja-Smith Z., Morales A.R., Romanelli R., et al. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy: role of metalloproteinases and pyridinoline cross links. Am J Pathol 148 (1996) 1639-1648
121. Spinale F.G., Coker M.L., Thomas C.V., et al. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 82 (1998) 482-495
122. Spinale F.G., Coker M.L., Krombach R.S., et al. Matrix metalloproteinase inhibition during developing congestive heart failure: effects on left ventricular geometry and function. Circ Res 85 (1999) 364-376
123. Ries C., and Petrides P.E. Cytokine regulation of matrix metalloproteinase activity and regulatory dysfunction in disease. Biol Chem 376 (1995) 345-355
124. Chancey A.L., Brower G.L., Peterson J.T., et al. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 105 (2002) 1983-1988
125. Thomas C.V., Coker M.L., Zellner J.L., et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97 (1998) 1708-1715
126. Diez J., Laviades C., Mayor G., et al. Increased serum concentration of procollagen peptides in essential hypertension. Relation to cardiac alteration. Circulation 91 (1995) 1450-1456
127. Querejeta R., Varo N., Lopez B., et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 101 (2000) 1729-1735
128. Poulsen S.H., Høst N.B., Jensen S.E., et al. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 101 (2000) 1527-1532
129. Jensen L.T., H-Petersen K., Toft P., et al. Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction. Circulation 81 (1990) 52-57
130. Høst N.B., Jensen L.T., Bendixen P.M., et al. The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol 76 (1995) 869-873
131. Sato Y., Kataoka K., Matsumori A., et al. Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. Heart 78 (1997) 505-508
132. Klappacher G., Franzen P., Haab D., et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 75 (1995) 913-918